Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
The global market for Tyrosine Kinase JAK Inhibitors was estimated to be worth US$ 30480 million in 2023 and is forecast to a readjusted size of US$ 550830 million by 2030 with a CAGR of 50.6% during the forecast period 2024-2030
The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
麻豆原创 competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42% market sharers.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tyrosine Kinase JAK Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Tyrosine Kinase JAK Inhibitors by region & country, by Type, and by Application.
The Tyrosine Kinase JAK Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tyrosine Kinase JAK Inhibitors.
麻豆原创 Segmentation
By Company
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
Segment by Type:
Tofacitinib
Ruxolitinib
Baricitinib
Segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Tyrosine Kinase JAK Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Tyrosine Kinase JAK Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Tyrosine Kinase JAK Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Tyrosine Kinase JAK Inhibitors Product Introduction
1.2 Global Tyrosine Kinase JAK Inhibitors 麻豆原创 Size Forecast
1.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Value (2019-2030)
1.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume (2019-2030)
1.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Price (2019-2030)
1.3 Tyrosine Kinase JAK Inhibitors 麻豆原创 Trends & Drivers
1.3.1 Tyrosine Kinase JAK Inhibitors Industry Trends
1.3.2 Tyrosine Kinase JAK Inhibitors 麻豆原创 Drivers & Opportunity
1.3.3 Tyrosine Kinase JAK Inhibitors 麻豆原创 Challenges
1.3.4 Tyrosine Kinase JAK Inhibitors 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Tyrosine Kinase JAK Inhibitors Players Revenue Ranking (2023)
2.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Company (2019-2024)
2.3 Global Tyrosine Kinase JAK Inhibitors Players Sales Volume Ranking (2023)
2.4 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Company Players (2019-2024)
2.5 Global Tyrosine Kinase JAK Inhibitors Average Price by Company (2019-2024)
2.6 Key Manufacturers Tyrosine Kinase JAK Inhibitors Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Tyrosine Kinase JAK Inhibitors Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Tyrosine Kinase JAK Inhibitors
2.9 Tyrosine Kinase JAK Inhibitors 麻豆原创 Competitive Analysis
2.9.1 Tyrosine Kinase JAK Inhibitors 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Tyrosine Kinase JAK Inhibitors Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tyrosine Kinase JAK Inhibitors as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tofacitinib
3.1.2 Ruxolitinib
3.1.3 Baricitinib
3.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Type
3.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Value, by Type (2019-2030)
3.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Value, by Type (%) (2019-2030)
3.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type
3.3.1 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume, by Type (2019-2030)
3.3.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume, by Type (%) (2019-2030)
3.4 Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Rheumatoid Arthritis (RA)
4.1.2 Polycythemia Vera (PCV)
4.1.3 Myelofibrosis (MF)
4.1.4 Others
4.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Application
4.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Value, by Application (2019-2030)
4.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Value, by Application (%) (2019-2030)
4.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application
4.3.1 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume, by Application (2019-2030)
4.3.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume, by Application (%) (2019-2030)
4.4 Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region
5.1.1 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (2019-2024)
5.1.3 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (2025-2030)
5.1.4 Global Tyrosine Kinase JAK Inhibitors Sales Value by Region (%), (2019-2030)
5.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Region
5.2.1 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Region (2019-2024)
5.2.3 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Region (2025-2030)
5.2.4 Global Tyrosine Kinase JAK Inhibitors Sales Volume by Region (%), (2019-2030)
5.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
5.4.2 North America Tyrosine Kinase JAK Inhibitors Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
5.5.2 Europe Tyrosine Kinase JAK Inhibitors Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
5.6.2 Asia Pacific Tyrosine Kinase JAK Inhibitors Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
5.7.2 South America Tyrosine Kinase JAK Inhibitors Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
5.8.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Tyrosine Kinase JAK Inhibitors Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Tyrosine Kinase JAK Inhibitors Sales Value
6.2.1 Key Countries/Regions Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.2.2 Key Countries/Regions Tyrosine Kinase JAK Inhibitors Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.3.2 United States Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.4.2 Europe Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.5.2 China Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.5.3 China Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.6.2 Japan Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.7.2 South Korea Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.8.2 Southeast Asia Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Tyrosine Kinase JAK Inhibitors Sales Value, 2019-2030
6.9.2 India Tyrosine Kinase JAK Inhibitors Sales Value by Type (%), 2023 VS 2030
6.9.3 India Tyrosine Kinase JAK Inhibitors Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Product Offerings
7.1.5 Pfizer Recent Development
7.2 Incyte
7.2.1 Incyte Company Information
7.2.2 Incyte Introduction and Business Overview
7.2.3 Incyte Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Incyte Tyrosine Kinase JAK Inhibitors Product Offerings
7.2.5 Incyte Recent Development
7.3 Novartis
7.3.1 Novartis Company Information
7.3.2 Novartis Introduction and Business Overview
7.3.3 Novartis Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Novartis Tyrosine Kinase JAK Inhibitors Product Offerings
7.3.5 Novartis Recent Development
7.4 Eli Lilly
7.4.1 Eli Lilly Company Information
7.4.2 Eli Lilly Introduction and Business Overview
7.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Product Offerings
7.4.5 Eli Lilly Recent Development
7.5 Gilead
7.5.1 Gilead Company Information
7.5.2 Gilead Introduction and Business Overview
7.5.3 Gilead Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Gilead Tyrosine Kinase JAK Inhibitors Product Offerings
7.5.5 Gilead Recent Development
7.6 Sanofi
7.6.1 Sanofi Company Information
7.6.2 Sanofi Introduction and Business Overview
7.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Product Offerings
7.6.5 Sanofi Recent Development
7.7 Galapagos
7.7.1 Galapagos Company Information
7.7.2 Galapagos Introduction and Business Overview
7.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Product Offerings
7.7.5 Galapagos Recent Development
7.8 AbbVie
7.8.1 AbbVie Company Information
7.8.2 AbbVie Introduction and Business Overview
7.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Product Offerings
7.8.5 AbbVie Recent Development
7.9 Vertex
7.9.1 Vertex Company Information
7.9.2 Vertex Introduction and Business Overview
7.9.3 Vertex Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Vertex Tyrosine Kinase JAK Inhibitors Product Offerings
7.9.5 Vertex Recent Development
7.10 Teva
7.10.1 Teva Company Information
7.10.2 Teva Introduction and Business Overview
7.10.3 Teva Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Teva Tyrosine Kinase JAK Inhibitors Product Offerings
7.10.5 Teva Recent Development
7.11 Astellas Pharma
7.11.1 Astellas Pharma Company Information
7.11.2 Astellas Pharma Introduction and Business Overview
7.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product Offerings
7.11.5 Astellas Pharma Recent Development
7.12 Celgene
7.12.1 Celgene Company Information
7.12.2 Celgene Introduction and Business Overview
7.12.3 Celgene Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Celgene Tyrosine Kinase JAK Inhibitors Product Offerings
7.12.5 Celgene Recent Development
7.13 CTI BioPharma
7.13.1 CTI BioPharma Company Information
7.13.2 CTI BioPharma Introduction and Business Overview
7.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.13.4 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product Offerings
7.13.5 CTI BioPharma Recent Development
8 Industry Chain Analysis
8.1 Tyrosine Kinase JAK Inhibitors Industrial Chain
8.2 Tyrosine Kinase JAK Inhibitors Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Tyrosine Kinase JAK Inhibitors Sales Model
8.5.2 Sales Channel
8.5.3 Tyrosine Kinase JAK Inhibitors Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
听
听
*If Applicable.